These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 36215113)
1. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force. Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):44-55. PubMed ID: 36215113 [TBL] [Abstract][Full Text] [Related]
2. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force. Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ Value Health; 2022 Oct; 25(10):1663-1672. PubMed ID: 36241338 [TBL] [Abstract][Full Text] [Related]
3. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229 [TBL] [Abstract][Full Text] [Related]
4. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966 [TBL] [Abstract][Full Text] [Related]
5. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243 [TBL] [Abstract][Full Text] [Related]
6. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430 [TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Building trust in real world evidence (RWE): moving transparency in RWE towards the randomized controlled trial standard. White R Curr Med Res Opin; 2023 Dec; 39(12):1737-1741. PubMed ID: 37787381 [TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
10. Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process. Oehrlein EM; Schoch S; Burcu M; McBeth JF; Bright J; Pashos CL; Willke R; Love TR; Mattingly TJ; Perfetto EM; Value Health; 2023 Jan; 26(1):28-38. PubMed ID: 35863944 [TBL] [Abstract][Full Text] [Related]
11. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155 [TBL] [Abstract][Full Text] [Related]
12. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. Patorno E; Schneeweiss S; Wang SV Diabetes Obes Metab; 2020 Apr; 22 Suppl 3(Suppl 3):45-59. PubMed ID: 32250527 [TBL] [Abstract][Full Text] [Related]
13. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL Value Health; 2012; 15(2):217-30. PubMed ID: 22433752 [TBL] [Abstract][Full Text] [Related]
14. FOUNTAIN: a modular research platform for integrated real-world evidence generation. Oberprieler NG; Pladevall-Vila M; Johannes C; Layton JB; Golozar A; Lavallee M; Liu F; Kubin M; Vizcaya D BMC Med Res Methodol; 2024 Oct; 24(1):224. PubMed ID: 39354358 [TBL] [Abstract][Full Text] [Related]
15. Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force. Powers JH; Patrick DL; Walton MK; Marquis P; Cano S; Hobart J; Isaac M; Vamvakas S; Slagle A; Molsen E; Burke LB Value Health; 2017 Jan; 20(1):2-14. PubMed ID: 28212963 [TBL] [Abstract][Full Text] [Related]
16. A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force. Bridges JFP; de Bekker-Grob EW; Hauber B; Heidenreich S; Janssen E; Bast A; Hanmer J; Danyliv A; Low E; Bouvy JC; Marshall DA Value Health; 2023 Feb; 26(2):153-162. PubMed ID: 36754539 [TBL] [Abstract][Full Text] [Related]
17. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E; Value Health; 2013; 16(2):231-50. PubMed ID: 23538175 [TBL] [Abstract][Full Text] [Related]
18. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291 [TBL] [Abstract][Full Text] [Related]
19. Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review. Khambholja K; Gehani M Value Health; 2023 Mar; 26(3):427-434. PubMed ID: 36210293 [TBL] [Abstract][Full Text] [Related]
20. Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Wailoo AJ; Hernandez-Alava M; Manca A; Mejia A; Ray J; Crawford B; Botteman M; Busschbach J Value Health; 2017 Jan; 20(1):18-27. PubMed ID: 28212961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]